Takeda Pharmaceutical Aktie
| 28,90EUR | 0,50EUR | 1,76% |
WKN: 853849 / ISIN: JP3463000004
Personal
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 47 347 | 49 095 | 49 281 | 47 455 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 75,38 | 82,03 | 86,52 | 96,55 | 0,00 |
Bilanz (in Mio. JPY) - Aktiva
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 593 642 | 2 397 956 | 2 558 580 | 2 521 192 | 3 090 503 |
| Summe Anlagevermögen | 10 584 376 | 11 559 794 | 12 550 212 | 11 727 152 | 12 362 610 |
| Summe Aktiva | 13 178 018 | 13 957 750 | 15 108 792 | 14 248 344 | 15 453 113 |
Bilanz (in Mio. JPY) - Passiva
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 7 494 496 | 7 603 080 | 7 834 788 | 7 312 365 | 7 678 314 |
| Summe Eigenkapital | 5 683 523 | 6 354 671 | 7 274 005 | 6 935 979 | 7 774 800 |
| Summe Passiva | 13 178 019 | 13 957 751 | 15 108 793 | 14 248 344 | 15 453 113 |
Adresse
| 2-1-1 Nihonbashi-Honcho, 103-8668 Osaka | |
| Telefon | +81 (3) 3278-2111 |
| Fax | +81 (3) 6204-2880 |
| Internet | http://www.takeda.com |
Management
|
Akiko Amakawa
Chief of Staff |
|
Andrew S. Plump
Director, President-Research & Development |
|
Christophe Weber
President, CEO & Representative Director |
|
Emiko Higashi
Independent Outside Director |
|
Gabriele Ricci
Chief Data & Technology Officer |
|
Giles Platford
President-International Business Unit |
|
Ian T. Clark
Independent Outside Director |
|
Jean-Luc Butel
Independent Outside Director |
|
John M. Maraganore
Independent Outside Director |
|
Kimberly A. Reed
Independent Outside Director |
|
Koji Hatsukawa
Independent Outside Director |
|
Lauren Duprey
Chief Transformation Officer |
|
Marcello Agosti
Head-Strategy & Portfolio Development |
|
Masami Iijima
Chairman |
|
Michel Orsinger
Independent Outside Director |
|
Miki Tsusaka
Independent Outside Director |
|
Mikuno Furuta
Director & Chief Financial Officer |
|
Natalie Furney
Global General Counsel |
|
Nicola Greenway
Chief Human Resources Officer |
|
Norimasa Takeda
Chief Accounting Officer & Corporate Controller |
|
Ramy Riad
President-Global Plasma Derived Therapies |
|
Steven H. Gillis
Independent Outside Director |
|
Teresa Marie Bitetti
President-Global Oncology Business Unit |
|
Yoshiaki Fujimori
Independent Outside Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.